These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 22808148)

  • 1. Pharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infection.
    Duwal S; Schütte C; von Kleist M
    PLoS One; 2012; 7(7):e40382. PubMed ID: 22808148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors.
    García-Lerma JG; Aung W; Cong ME; Zheng Q; Youngpairoj AS; Mitchell J; Holder A; Martin A; Kuklenyik S; Luo W; Lin CY; Hanson DL; Kersh E; Pau CP; Ray AS; Rooney JF; Lee WA; Heneine W
    J Virol; 2011 Jul; 85(13):6610-7. PubMed ID: 21525346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.
    Kiser JJ; Fletcher CV; Flynn PM; Cunningham CK; Wilson CM; Kapogiannis BG; Major-Wilson H; Viani RM; Liu NX; Muenz LR; Harris DR; Havens PL;
    Antimicrob Agents Chemother; 2008 Feb; 52(2):631-7. PubMed ID: 18025112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir.
    Pruvost A; Negredo E; Théodoro F; Puig J; Levi M; Ayen R; Grassi J; Clotet B
    Antimicrob Agents Chemother; 2009 May; 53(5):1937-43. PubMed ID: 19273671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults.
    Ruane PJ; DeJesus E; Berger D; Markowitz M; Bredeek UF; Callebaut C; Zhong L; Ramanathan S; Rhee MS; Fordyce MW; Yale K
    J Acquir Immune Defic Syndr; 2013 Aug; 63(4):449-55. PubMed ID: 23807155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects.
    Van Rompay KK; Durand-Gasselin L; Brignolo LL; Ray AS; Abel K; Cihlar T; Spinner A; Jerome C; Moore J; Kearney BP; Marthas ML; Reiser H; Bischofberger N
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3144-60. PubMed ID: 18573931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age-related differences in plasma and intracellular tenofovir concentrations in HIV-1-infected children, adolescents and adults.
    Baheti G; King JR; Acosta EP; Fletcher CV
    AIDS; 2013 Jan; 27(2):221-5. PubMed ID: 23032419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants.
    Flynn PM; Mirochnick M; Shapiro DE; Bardeguez A; Rodman J; Robbins B; Huang S; Fiscus SA; Van Rompay KK; Rooney JF; Kearney B; Mofenson LM; Watts DH; Jean-Philippe P; Heckman B; Thorpe E; Cotter A; Purswani M;
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5914-22. PubMed ID: 21896911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emtricitabine/tenofovir disoproxil fumarate: a review of its use in HIV-1 pre-exposure prophylaxis.
    Plosker GL
    Drugs; 2013 Mar; 73(3):279-91. PubMed ID: 23444256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence.
    Celum C; Baeten JM
    Curr Opin Infect Dis; 2012 Feb; 25(1):51-7. PubMed ID: 22156901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency?
    Havens PL; Kiser JJ; Stephensen CB; Hazra R; Flynn PM; Wilson CM; Rutledge B; Bethel J; Pan CG; Woodhouse LR; Van Loan MD; Liu N; Lujan-Zilbermann J; Baker A; Kapogiannis BG; Gordon CM; Mulligan K;
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5619-28. PubMed ID: 24002093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial.
    Celum C; Morrow RA; Donnell D; Hong T; Hendrix CW; Thomas KK; Fife KH; Nakku-Joloba E; Mujugira A; Baeten JM;
    Ann Intern Med; 2014 Jul; 161(1):11-9. PubMed ID: 24979446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single dose pharmacokinetics of oral tenofovir in plasma, peripheral blood mononuclear cells, colonic tissue, and vaginal tissue.
    Louissaint NA; Cao YJ; Skipper PL; Liberman RG; Tannenbaum SR; Nimmagadda S; Anderson JR; Everts S; Bakshi R; Fuchs EJ; Hendrix CW
    AIDS Res Hum Retroviruses; 2013 Nov; 29(11):1443-50. PubMed ID: 23600365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tenofovir-based preexposure prophylaxis for HIV infection among African women.
    Marrazzo JM; Ramjee G; Richardson BA; Gomez K; Mgodi N; Nair G; Palanee T; Nakabiito C; van der Straten A; Noguchi L; Hendrix CW; Dai JY; Ganesh S; Mkhize B; Taljaard M; Parikh UM; Piper J; Mâsse B; Grossman C; Rooney J; Schwartz JL; Watts H; Marzinke MA; Hillier SL; McGowan IM; Chirenje ZM;
    N Engl J Med; 2015 Feb; 372(6):509-18. PubMed ID: 25651245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emtricitabine/tenofovir in the treatment of HIV infection: current PK/PD evaluation.
    Uglietti A; Zanaboni D; Gnarini M; Maserati R
    Expert Opin Drug Metab Toxicol; 2012 Oct; 8(10):1305-14. PubMed ID: 22943210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abacavir and tenofovir disoproxil fumarate co-administration results in a nonadditive antiviral effect in HIV-1-infected patients.
    Goicoechea M; Jain S; Bi L; Kemper C; Daar ES; Diamond C; Ha B; Flaherty J; Sun S; Richman D; Louie S; Haubrich R;
    AIDS; 2010 Mar; 24(5):707-16. PubMed ID: 20087154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RMP-02/MTN-006: A phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate.
    Anton PA; Cranston RD; Kashuba A; Hendrix CW; Bumpus NN; Richardson-Harman N; Elliott J; Janocko L; Khanukhova E; Dennis R; Cumberland WG; Ju C; Carballo-Diéguez A; Mauck C; McGowan I
    AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1412-21. PubMed ID: 22943559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of a significant drug interaction between raltegravir and tenofovir.
    Wenning LA; Friedman EJ; Kost JT; Breidinger SA; Stek JE; Lasseter KC; Gottesdiener KM; Chen J; Teppler H; Wagner JA; Stone JA; Iwamoto M
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3253-8. PubMed ID: 18625763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings.
    Myers GM; Mayer KH
    AIDS Patient Care STDS; 2011 Feb; 25(2):63-71. PubMed ID: 21284497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission.
    Patterson KB; Prince HA; Kraft E; Jenkins AJ; Shaheen NJ; Rooney JF; Cohen MS; Kashuba AD
    Sci Transl Med; 2011 Dec; 3(112):112re4. PubMed ID: 22158861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.